We investigated whether UGT1A1 polymorphisms are associated with the prognosis of ovarian cancer patients treated with irinotecan. UGT1A1 genotypes were analyzed in 11 stage I ovarian clear cell carcinoma patients who received irinotecan as first-line therapy. Progression-free survival, overall survival and adverse events were also assessed for each genotype. Three patients harbored UGT1A1*1/*6 while another three harbored UGT1A1*1/*28. Two patients with a wildtype genotype experienced recurrence and one died, whereas no recurrence or death was observed in patients with heterozygous genotypes. Adverse events tended to be more severe in patients with UGT1A1*6 and *28, although progression-free survival and overall survival rates tended to be better than in wild-type; the differences were not significant. We conclude that UGT1A1 polymorphisms have the potential to be a prognostic marker of irinotecan treatment.
Introduction
Ovarian cancer prognosis remains poor despite recent treatment advances. Irinotecan, a topoisomerase inhibitor that is used to treat many solid tumors, has been shown to be effective against ovarian cancer.
Irinotecan is a prodrug that is metabolized in the liver to SN-38, a topoisomerase inhibitor. SN-38 is subsequently inactivated through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) to produce SN-38 glucuronide (SN-38G) (1) . It is well known that UGT1A1 gene polymorphisms predict adverse effects of irinotecan. Homozygous UGT1A1*6 and *28, or compound heterozygous UGT1A1*6/*28, are thought to be poor metabolizers, and portend a higher risk of severe adverse effects such as neutropenia and diarrhea (2) .
Irinotecan doses vary among cancers; prior studies considered <150, 150-250 and >250 mg/m 2 to be low, intermediate and high
doses, respectively (3) . Irinotecan is usually administered to gynecologic cancer patients in low doses; however, we previously reported that UGT1A1 polymorphisms were associated with adverse effects despite such low doses (4) . However, the appropriate irinotecan dose that takes into account UGT1A1 polymorphisms is still controversial. Antitumor vs. adverse effects are two sides of the same coin. In patients who have UGT1A1*6 or *28 haplotypes, the area under the concentration curve (AUC) ratio of SN-38G/SN-38 is significantly reduced (5) . One hypothesis is that the antitumor effect may increase concomitantly with adverse effects, leading to a better prognosis. If so, it is worth considering whether the irinotecan dose can be increased to optimal levels of efficacy in UGT1A1 wild-type patients as well.
To our knowledge, no study has analyzed the relationship between UGT1A1 polymorphisms and long-term prognosis in ovarian cancer patients treated with irinotecan. Therefore, we retrospectively examined the association between UGT1A1 polymorphisms and the prognosis of stage I ovarian clear cell carcinoma.
Patients and methods

Patients
A total of 61 ovarian cancer patients were treated with irinotecancontaining chemotherapy at Keio University Hospital between January 2000 and December 2010. Of all, 42 patients were treated for recurrent ovarian cancer while 19 received first-line chemotherapy. In order to estimate the prognosis accurately, we limited the subjects to those satisfying the following criteria: (i) stage I (International Federation of Gynecology and Obstetrics; FIGO 1988), (ii) clear cell carcinoma histology, (iii) received first-line chemotherapy and (iv) treatment comprised of irinotecan and cisplatin combination therapy. Overall, 11 patients met these criteria, and collected whole blood samples were analyzed retrospectively. Informed consent was obtained in writing from all patients before enrollment. The study was approved by the ethics committee of the School of Medicine, Keio University.
Determination of UGT1A1 gene polymorphisms
Genomic DNA was extracted by standard procedures from peripheral blood, which had been stored at −80°C until analysis. We examined UGT1A1*6 (211 G→A) and UGT1A1*28 ([TA] 6 TAA→[TA] 7 TAA) alleles as previously described (4, 6) . UGT1A1*1/*1 was defined as wild-type (normally functioning phenotype). 
Treatment regimen
Treatment and adverse effects evaluation
We assessed progression-free survival (PFS) and overall survival (OS) rates. PFS was defined as the interval between the first day of irinotecan-containing therapy administration and the day the first relapse or progression was observed with imaging. OS was defined as the interval between the first day of irinotecan-containing therapy administration to the date of death or last follow-up visit to the hospital. Physical examinations and blood tests were retrospectively reviewed to evaluate toxicity and adverse effects; grades were assessed according to the Common Terminology Criteria for Adverse Events, version 4.0. The monitoring period for adverse events, including determination of the worst grade after irinotecan therapy, commenced 6 weeks after the final administration of irinotecan.
Statistical methods
The data were analyzed using IBM SPSS for Windows version 23.0 (IBM Co., Armonk, NY, USA). OS and PFS curves were plotted using the Kaplan-Meier method; differences between UGT1A1 genotypes were analyzed using the log-rank test. The adverse effects of each genotype were compared using Fisher's exact test. P < 0.05 were considered significant.
Results
The characteristics of the 11 patients are shown in Table 1 . The median age was 51 years (range: 31-60 years). All patients received three or more cycles of irinotecan and cisplatin combination therapy as the first-line chemotherapy. One stage Ia patient (11) received only left adnexectomy and right ovary biopsy because she hoped to maintain fertility; all others received hysterectomy, bilateral adnexectomy, pelvic and paraaortic lymphadenectomy and omentectomy. Three of 11 patients were heterozygous for UGT1A1*6 and another three carried *28 each (heterozygous group). Neither homozygosity for UGT1A1*6 nor *28 nor compound heterozygosity for UGT1A1*6/ *28 was detected in this population. Ovarian cancer recurred in two patients in the UGT1A1 wild-type group, and one died of tumor progression. No recurrence was observed in the heterozygous group.
UGT1A1 polymorphisms and adverse effects profile
All six patients in the heterozygous group had neutropenia of grades ≥3, whereas two patients had grade 3 and another three had grade 2 neutropenia in the wild-type group (P = 0.061). The number of patients with other adverse effects of grades ≥3 was four in the heterozygous group and one in the wild-type group (P = 0.175). Additionally, four of six patients required dose reduction due to the adverse effects in the heterozygous group, compared with two of five who required dose reduction in the wild-type group (P = 0.392). Statistical analysis showed no significant difference, likely because of the small sample size; however, we observed a trend that patients who were heterozygous for UGT1A1*6 or *28 had a higher risk of adverse effects than wild-type; these were also of greater severity.
UGT1A1 polymorphisms and prognosis
Kaplan-Meier curves for PFS and OS are shown in Fig. 1 . The median OS and PFS rates of the heterozygous group were both 88.5 months (range: 63.4-145.8 months), whereas these rates were 83.3 months (range: 44.8-149.0 months) and 83.3 months (range: 16.8-149.0 months) in the wild-type group, respectively. No significant difference was observed between the UGT1A1 genotypes for PFS (P = 0.101) or OS (P = 0.221), again likely because of the small sample size; however, the heterozygous group tended to have a better prognosis because no recurrence or death occurred.
Discussion
The UGT1A1 genotype profile varies by ethnicity (7, 8) . A previous report showed that the frequency of the *28 and *6 haplotypes was 38.8 and 0.7% in Caucasians and 9.7 and 15.7% in Japanese individuals, respectively (9). In our study, 3 of 11 patients harbored *6, indicating its prevalence in the Japanese population.
In clinical practice, patients with UGT1A1*6/*6, *28/*28, and *6/*28 are considered poor metabolizers with an increased risk of severe adverse events. However, Minami et al. reported a correlation between the number of *6 or *28 haplotypes and SN-38G/SN-38 AUC ratios (5) . In their study, the SN-38G/SN-38 AUC ratio in patients without *6 or *28 was 5.55 (range: 4.13-7.26); that in patients with one haplotype harboring *6 or *28 was 3.62 (range: 2.74-5.18), and the ratio in patients with two haplotypes harboring *6 or *28 was 2.07 (range: 1.45-3.62).
We showed more severe adverse effects in *6 or *28 heterozygous patients compared with wild-type; furthermore, there were no recurrences in the heterozygous patients. These findings support the hypothesis that UGT1A1*6 and *28 alleles may increase the SN-38 blood concentration levels, and hence the concomitant antitumor effects. Cervical cancer patients with heterozygosity for *6 or *28 were previously shown to exhibit significantly better clinical response to neoadjuvant chemotherapy (10) . FOLFIRI containing irinotecan was also more effective in colorectal cancer patients with UGT1A1 *28/*28 (11) .
The relationship between UGT1A1 genotypes and irinotecan efficacy is still debated. Several studies (12, 13) showed no significant association between prognosis and genotypes; however, the subjects' backgrounds in these studies differed from those in ours. The dose of irinotecan administered to treat colorectal cancer is usually high (≥150 mg/m 2 ), and therefore might be effective enough to mask significant differences in prognosis between UGT1A1 genotypes. In other words, the low irinotecan dose used for ovarian cancer may not be optimal for some patients. In fact, our results showed a trend towards better prognosis in heterozygous group patients even though their irinotecan doses had been reduced owing to adverse effects. Our data suggest that the irinotecan dose in patients with UGT1A1*6 and *28 alleles should be increased above the current dose setting in wildtype patients to attain optimal antitumor efficacy.
Irinotecan therapy for gynecologic cancer includes both monotherapy and combination therapy, often with cisplatin. In this study, all patients received irinotecan and cisplatin combination therapy. The association between UGT1A1 polymorphisms and adverse events related to irinotecan and cisplatin combination therapy have been already reported (14) . To date, no genetic biomarkers that can predict the risk of adverse events for cisplatin therapy alone have been reported; we did not take into account the individual effect of cisplatin in this study.
This study is limited by its small sample size and the preliminary nature of the data. However, a strength of the study is the uniformity of patient backgrounds, such as surgical stage, histology, dose, age and treatment schedule. Only patient 11 received three cycles of chemotherapy following fertility-sparing surgery; this patient was diagnosed with stage Ia clear cell ovarian cancer when she was 34-year old. Several studies of fertility-sparing surgery for ovarian cancer patients have been performed to date. Satoh et al. reported 5-year OS and recurrence-free survival for stage Ia clear cell histology ovarian cancer to both be 100% (15) ; the median number of adjuvant chemotherapy cycles for such patients was 3. Therefore, this patient was likely comparable to others in our study. 
